Syros Pharmaceuticals Inc (NASDAQ:SYRS)’s share price was up 3.2% on Tuesday . The stock traded as high as $9.89 and last traded at $9.69, with a volume of 58,628 shares trading hands. The stock had previously closed at $9.39.

Several equities analysts recently weighed in on SYRS shares. Piper Jaffray Cos. started coverage on shares of Syros Pharmaceuticals in a report on Monday, July 25th. They set an “overweight” rating and a $20.00 target price on the stock. JMP Securities started coverage on shares of Syros Pharmaceuticals in a report on Monday, July 25th. They set an “outperform” rating and a $22.00 target price on the stock. HC Wainwright assumed coverage on shares of Syros Pharmaceuticals in a report on Monday, July 18th. They set a “neutral” rating and a $10.00 target price on the stock. Wedbush assumed coverage on shares of Syros Pharmaceuticals in a report on Monday, July 25th. They issued an “outperform” rating and a $18.00 price objective on the stock. Finally, Cowen and Company assumed coverage on shares of Syros Pharmaceuticals in a report on Monday, July 25th. They issued an “outperform” rating on the stock. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $17.50.

The company has a 50-day moving average price of $0.00 and a 200 day moving average price of $0.00. The stock’s market cap is $92.53 million.

In related news, major shareholder Redmile Group, Llc acquired 432,746 shares of the company’s stock in a transaction on Wednesday, July 6th. The shares were purchased at an average price of $12.50 per share, for a total transaction of $5,409,325.00. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Robert Nelsen acquired 400,000 shares of the company’s stock in a transaction on Wednesday, July 6th. The stock was bought at an average price of $12.50 per share, for a total transaction of $5,000,000.00. The disclosure for this purchase can be found here.

Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on developing treatments for cancer and immune-mediated diseases. The Company’s gene control platform focuses on identifying gene control targets linked to genomically defined patient populations, and drugging gene control targets.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.